The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System. The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.
The primary safety endpoint is Freedom from Major Adverse Device Effects (MADEs) through 6 months. The primary effectiveness endpoint is Defibrillation Performance: Successful induced ventricular arrhythmia (IVA) test in the final system configuration. Up to 40 Investigational Sites Worldwide will participate with up to 280 subjects enrolled in the study. At least 50% of subjects will be enrolled at sites in the United States. Subjects meeting indications for ICD therapy who do not require permanent bradycardia pacing will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to an EV-ICD Pulse Generator positioned in a left pectoral or left lateral location. The Parasternal EV-ICD System will be tested to verify appropriate sensing and defibrillation. Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to be ongoing for a minimum of 2.5 years from the date of first enrollment. Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 6-month visit.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
280
Subjects will receive the Atala™ lead and EV-ICD pulse generator being evaluated in the study.
Honor Health
Scottsdale, Arizona, United States
NOT_YET_RECRUITINGSt. Bernards Heart and Vascular
Jonesboro, Arkansas, United States
RECRUITINGUC San Diego Health
La Jolla, California, United States
NOT_YET_RECRUITINGProvidence Medical Foundation
Orange, California, United States
Freedom from MADEs
Freedom from Major Adverse Device Effects (MADEs)
Time frame: Through 6 months post-implant
Successful IVA Test
Successful induced ventricular arrhythmia (IVA) test in the final system configuration
Time frame: At the time of procedure and up to 60 days post-implant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cedars-Sinai Medical Center
Santa Monica, California, United States
NOT_YET_RECRUITINGMedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
NOT_YET_RECRUITINGMount Sinai Medical Center of Florida
Miami Beach, Florida, United States
NOT_YET_RECRUITINGAdventHealth
Orlando, Florida, United States
NOT_YET_RECRUITINGEmory University
Atlanta, Georgia, United States
RECRUITINGEndeavor Health
Glenview, Illinois, United States
RECRUITING...and 25 more locations